Healthcare Industry News: BioVex
News Release - May 12, 2015
Autonomic Technologies Raises USD 38M in a Transatlantic Series D FinancingREDWOOD CITY, CA--(Healthcare Sales & Marketing Network) - Autonomic Technologies™, Inc. (ATI™), developer and manufacturer of Pulsante™, a microstimulator to treat severe headaches, today announced the closing of a series D round of financing for $38M. The round was led by Edmond de Rothschild Investment Partners (EdRIP), the Paris based venture capital firm, syndicated with Forbion Capital Partners, from Naarden, the Netherlands. The existing investors Kleiner Perkins Caufield and Byers, InterWest Partners, Novartis Venture Fund, Aberdare Ventures and the Cleveland Clinic strongly supported the financing as well. Olivier Litzka, Partner at Edmond de Rothschild Investment Partners (EdRIP) and Martien van Osch, Managing Partner at Forbion Capital Partners (Forbion) will join ATI's Board of Directors.
ATI has started commercialization of the Pulsante microstimulator in Europe and established Autonomic Technologies Europe GmbH, a wholly owned subsidiary in Germany, to further expand European commercialization. In addition, the company will use proceeds from the financing to fund the ongoing IDE study in the USA.
"The investments from our new European investors together with the support from our existing investors provide recognition of ATI's strong clinical data and our unique Pulsante microstimulator for severe headache," said Ben Pless, President and Chief Executive Officer of Autonomic Technologies. "We are now well financed to further build out our leadership position in the growing field of neurostimulation in headache, expanding our launch to other countries in Europe and expanding the clinical evidence base of our minimally invasive treatment into other indications."
"Interested in and following the extremely dynamic field of neuromodulation/neurostimulation we were attracted to Autonomic Technologies Inc and its Pulsante microstimulator through very convincing clinical data in cluster headache, a disease of extreme pain with limited treatment options" said Olivier Litzka, Partner at EdRIP, "With ATI showing that it is able to professionally commercialize Pulsante in Europe, it makes it a very suitable investment for EdRIP."
"Pulsante microstimulator has already convinced many KOLs and patients in Europe and the US, and we therefore see a significant market potential for this treatment solution, which is brought forward by a very strong and experienced team." added Martien van Osch, Managing Partner at Forbion.
About Autonomic Technologies
Autonomic Technologies, Inc. (ATI™) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of innovative therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache. For more information, please visit: www.pulsante.eu or www.ati-spg.com.
About Edmond de Rothschild Investment Partners
Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialized in asset management and private banking (EUR 133.6bn under management, nearly 2,800 employees spread across 31 offices, branches and subsidiaries throughout the world). Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de Rothschild.
Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It currently has more than EUR 1.3 billion under management which is being invested primarily as life sciences venture capital and growth capital.
Within Edmond de Rothschild Investment Partners, its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The Team has raised EUR 450 million through its Biodiscovery franchise and is currently investing BioDiscovery 4. Since inception in 2001, BioDiscovery Funds have invested in 50 companies, of which 15 have been sold and 14 listed on public financial markets, while 18 are active in the portfolios.
BioDiscovery Funds, including BioDiscovery 4, are venture capital funds dedicated to professional investors. These funds are not authorized by the Autorité des Marchés Financiers and may adopt special investment rules. For more information, please visit: www.edrip.fr.
About Forbion Capital Partners
Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, Munich, Germany and representation in Boston, US. Forbion invests in life sciences companies in drug discovery & development as well as medical device companies addressing substantial unmet medical needs. Forbion's investment team of ten investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda (ACOR), Fovea, Insmed (INSM), PanGenetics, Argenta Discovery, BioVex, Pathway Medical, CircuLite, bluebird bio (BLUE), uniQure (QURE), Argos (ARGS), arGEN-X (ARGX.BR), Santaris and PneumRx. Forbion also operates a joint venture with BioGeneration Ventures, who manages two separate seed and early stage funds focused on Benelux. Including the new fund FCF III, Forbion manages EUR 540M across 5 funds. Its investors include the EIF through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities.
For more information, please visit: www.forbion.com.
About Kleiner Perkins Caufiled & Byers
KleinerPerkins Caufield & Byers (KPCB) partners with the brightest entrepreneurs to turn disruptive ideas into world-changing businesses. The firm has helped build pioneering companies like Amazon, Electronic Arts, Genentech, Google,Nest, Netscape, and Twitter. KPCB offers entrepreneurs years of operating experience, puts them at the center of a vast and influential network, and accelerates their success through expertise and support in recruiting, product design and delivery, business development, strategic partnerships and brandbuilding. KPCB invests in all stages from seed and incubation to growth companies and operates from offices in Menlo Park, San Francisco, Shanghai and Beijing. For more information, please visit: www.kpcb.com.
About Novartis Venture Fund
Founded in 1996, Novartis Venture Funds currently manage over $800 million in committed capital. As a financially driven corporate life science investor, the Novartis Venture Funds invest in those companies which have the potential to lead the next innovation wave in our core therapeutic fields or explore new business areas that will be critical to patient care. Since its formation, Novartis Venture Funds have invested in more than 70 companies in the biotech and medical device sectors. The Novartis Venture Funds' team of ten investment professionals located in Basel Switzerland and Cambridge, MA brings together extensive expertise in life sciences and venture capital. For more information, please visit: www.venturefund.novartis.com.
About InterWest Partners
For more than 30 years, InterWest has partnered with exceptional entrepreneurs to build winning technology and life sciences companies. With more than 200 years of combined operating and investing experience, the firm's investing team has raised $2.8B, completed more than 70 IPOs, and participated in nearly 60 upside acquisitions. As the firm invests InterWest X, a $650M fund, the InterWest team continues to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company. For more information please visit: www.interwest.com.
About Aberdare Ventures
Formed in 1999, Aberdare Ventures is a San Francisco-based venture capital firm investing in visionary entrepreneurs and technologies that are transforming healthcare with new biological, engineering, and information technologies. The firm has attracted and partnered with many superior early stage companies such as Ironwood, Pharmion, Clovis Oncology and MC10, repeatedly backing start-up's that have grown to values exceeding $1 billion. The team of six investment professionals oversees a committed capital base in excess of $400 million in aggregate. For more information please visit: www.aberdare.com.
About the Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, eight community hospitals, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, scheduled to begin seeing patients in 2015, Cleveland Clinic Abu Dhabi. In 2013, there were 5.5 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. For more information, please visit us at www.clevelandclinic.org.
Source: Autonomic Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.